Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA:603392)
China · Delayed Price · Currency is CNY 60.05
-0.66 (-1.09%)
Sep 12, 2025, 3:00 PM CST
SHA:603392 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -298.28 | 106.24 | 1,248 | 4,736 | 2,021 | 677 | Upgrade |
Depreciation & Amortization | 313.78 | 290.25 | 231.51 | 151.9 | 105.28 | 84.47 | Upgrade |
Other Amortization | 40.5 | 27.99 | 60.55 | 6.63 | 5.03 | 2.07 | Upgrade |
Loss (Gain) From Sale of Assets | -7.88 | -7.92 | -0.22 | -0.06 | 0.72 | -0.42 | Upgrade |
Asset Writedown & Restructuring Costs | 1.53 | 0.53 | 224.01 | 2.8 | 0.25 | - | Upgrade |
Loss (Gain) From Sale of Investments | -133.77 | -146.34 | -123.56 | -46.09 | -11.25 | -13.6 | Upgrade |
Provision & Write-off of Bad Debts | 43.18 | 15.04 | -23.27 | 90.61 | 83.95 | 24.07 | Upgrade |
Other Operating Activities | 122.74 | 83.56 | 199.37 | 129.61 | 96.86 | 46.91 | Upgrade |
Change in Accounts Receivable | 707.28 | 940.33 | 984.81 | -1,778 | -1,707 | -487.31 | Upgrade |
Change in Inventory | -226.95 | -58.18 | -218.34 | -296.47 | -222.97 | -190.68 | Upgrade |
Change in Accounts Payable | -330.37 | -805.75 | -935.62 | 1,116 | 1,322 | 287.39 | Upgrade |
Change in Other Net Operating Assets | -5.28 | -5.28 | - | - | -0 | - | Upgrade |
Operating Cash Flow | 159.98 | 355.08 | 1,538 | 4,133 | 1,682 | 468.21 | Upgrade |
Operating Cash Flow Growth | -89.34% | -76.91% | -62.79% | 145.70% | 259.23% | 71.70% | Upgrade |
Capital Expenditures | -862.81 | -887.35 | -1,160 | -929.91 | -1,048 | -390.44 | Upgrade |
Sale of Property, Plant & Equipment | 14.81 | 16.06 | 0.72 | 0.89 | 8.19 | 2.73 | Upgrade |
Cash Acquisitions | - | - | -0.71 | - | - | - | Upgrade |
Investment in Securities | -872.44 | -794.66 | -960.3 | -2,589 | 14.39 | 86.52 | Upgrade |
Other Investing Activities | 158.12 | 162.59 | 66.23 | 3.9 | 11.11 | 5.78 | Upgrade |
Investing Cash Flow | -1,562 | -1,503 | -2,054 | -3,514 | -1,014 | -295.4 | Upgrade |
Long-Term Debt Issued | - | 231.24 | 186.44 | 351.6 | 240.35 | 90.37 | Upgrade |
Total Debt Issued | 310.35 | 231.24 | 186.44 | 351.6 | 240.35 | 90.37 | Upgrade |
Long-Term Debt Repaid | - | -272.81 | -170.57 | -352.46 | -92.06 | -33.77 | Upgrade |
Net Debt Issued (Repaid) | -16.05 | -41.57 | 15.87 | -0.86 | 148.29 | 56.6 | Upgrade |
Issuance of Common Stock | - | 78.21 | 54 | 3,461 | 10 | 342.28 | Upgrade |
Repurchase of Common Stock | -187.71 | -238.44 | -15.65 | -200.17 | - | - | Upgrade |
Common Dividends Paid | -3.76 | -410.18 | -907.47 | -127.49 | -112.74 | -1.65 | Upgrade |
Other Financing Activities | 37.35 | -0.76 | -40 | -5.68 | 7.23 | -17.43 | Upgrade |
Financing Cash Flow | -170.17 | -612.74 | -893.26 | 3,127 | 52.79 | 379.79 | Upgrade |
Foreign Exchange Rate Adjustments | 2.1 | 4.38 | 7.62 | 26.26 | -8.75 | -9.01 | Upgrade |
Net Cash Flow | -1,570 | -1,757 | -1,402 | 3,772 | 711.88 | 543.59 | Upgrade |
Free Cash Flow | -702.83 | -532.27 | 378.15 | 3,203 | 634.16 | 77.77 | Upgrade |
Free Cash Flow Growth | - | - | -88.19% | 405.03% | 715.43% | -29.73% | Upgrade |
Free Cash Flow Margin | -40.79% | -23.71% | 6.86% | 28.63% | 11.03% | 3.30% | Upgrade |
Free Cash Flow Per Share | -0.52 | -0.40 | 0.30 | 2.56 | 0.52 | 0.07 | Upgrade |
Cash Income Tax Paid | 113.84 | 114.16 | 537.3 | 1,164 | 295.76 | 145.34 | Upgrade |
Levered Free Cash Flow | -688.64 | -24.09 | -308.83 | 1,738 | -4.04 | -218.2 | Upgrade |
Unlevered Free Cash Flow | -676.94 | -18.89 | -304.55 | 1,743 | -0.48 | -217.15 | Upgrade |
Change in Working Capital | 78.18 | -14.26 | -278.25 | -938.6 | -620.35 | -352.28 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.